After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.
Profiting from these companies' steady long-term gains requires patience.
Novo Nordisk (NVO) is developing new types of insulin, such as a pill-based form, in response to growing competitive pressures.
Novo is 'not yet screamingly cheap, but it is certainly approaching great value.'
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.